The GPCB issues a ₹1 crore environmental compensation notice to Piramal Pharma. In this case, the company faces more severe penalties for the closure of its manufacturing facility in Dahej, Gujarat. The pharmaceutical company announced that it received the interim notice for compensation for environmental damage on the 10th of February, 2026. The legal proceeding is part of the compliance mechanism for India’s environmental regulations, as communicated to stock exchanges.

Escalation of Regulatory Action at Dahej Facility

The notice of compensation was issued by the Gujarat Pollution Control Board (GPCB) after the board had earlier issued a closure order for Piramal Pharma’s Dahej plant under Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974. The company announced the earlier closure order on February 4, 2026.

According to regulatory filings, the compensation notice is a further step in enforcement related to non-compliance at the facility. The Dahej site is one of the company’s important manufacturing units, and the action is closely monitored.

Also Read: U.S. Set To Roll Back Core Climate Regulation Basis By Scrapping Endangerment Finding, White House Says

Company Response and Legal Engagement

Piramal Pharma says it’s working closely with regulators to resolve issues in line with the court’s guidance and is in discussions to reach a quick resolution through the legal system. The company wants people to know it’s complying with environmental regulations and fully cooperating with the authorities. Management says they’re following all the right steps to address the issues raised by the pollution control board.

In addition, company officials have made it clear that, as the compensation notice is interim, there is still room for further representation to the regulatory agency. Piramal must also submit specific documents to support its case, and operations will remain in place in accordance with environmental laws. Again, the company assured that it would keep developments on this subject under review and update stakeholders in due course.

Also Read: EU Sued Over Controversial Lithium Mine In Portugal By Environmental Groups

Financial Impact and Disclosure Obligations

In its disclosure, Piramal Pharma made it clear that, aside from the ₹1 crore payment for environmental damage and an earlier bank guarantee, nothing else is affecting its finances or daily operations. Manufacturing and business are running as usual.

They shared this update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and informed both BSE Limited and the National Stock Exchange of India Limited, and they want to keep investors and regulators in the loop. As the process continues, the ₹1 crore environmental compensation notice to Piramal Pharma stands out as another sign that regulators are closely monitoring how companies manage environmental compliance.

Also Read: Uncharted Tremors: Deep‑Mantle Earthquakes Are Mapped For The First Time